Pmv Pharmaceuticals Inc Cash Flow Conversion Efficiency
Pmv Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Pmv Pharmaceuticals Inc (PMVP) has a cash flow conversion efficiency ratio of -0.204x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.58 Million) by net assets ($71.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pmv Pharmaceuticals Inc (2018–2025)
Cash flow conversion efficiency of Pmv Pharmaceuticals Inc from 2018 to 2025. This chart illustrates how Pmv Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PMVP stock price for real-time trading data and today's change.
Pmv Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Pmv Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pmv Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pmv Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see market value of Pmv Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BARK, Inc.
NYSE:BARK
|
-0.046x |
|
Konka Group Co Ltd
SHE:200016
|
0.069x |
|
PT DFI Retail Nusantara Tbk
JK:HERO
|
0.026x |
|
Careium AB
ST:CARE
|
0.037x |
|
myNEWS Holdings Bhd
KLSE:5275
|
0.149x |
|
Vissem Electronics Co. Ltd
KQ:072950
|
0.023x |
|
Huadian Ener-B
SHG:900937
|
0.052x |
|
5E Advanced Materials Inc
AU:5EA
|
-0.057x |
Annual Cash Flow Conversion Efficiency for Pmv Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Pmv Pharmaceuticals Inc from 2018 to 2025. Review how financially flexible is Pmv Pharmaceuticals Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $104.71 Million | $-73.58 Million | -0.703x | -141.26% |
| 2024-12-31 | $176.08 Million | $-51.28 Million | -0.291x | -18.10% |
| 2023-12-31 | $225.69 Million | $-55.66 Million | -0.247x | +4.84% |
| 2022-12-31 | $246.03 Million | $-63.76 Million | -0.259x | -71.71% |
| 2021-12-31 | $308.56 Million | $-46.57 Million | -0.151x | -65.56% |
| 2020-12-31 | $359.12 Million | $-32.74 Million | -0.091x | -129.12% |
| 2019-12-31 | $-70.47 Million | $-22.07 Million | 0.313x | -4.82% |
| 2018-12-31 | $-46.14 Million | $-15.18 Million | 0.329x | -- |
About Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. an… Read more